Vir Biotechnology, Inc.(VIR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VIR Vir Biotechnology, Inc.

Post-Mkt 05-11 17:13:22 EDT

9.29

+0.17

+1.86%

盘后9.12

-0.17-1.83%

16:26 EDT

High9.65	Low9.12	Vol1.39M
Open9.15	D1 Closing9.12	Amplitude5.76%
Mkt Cap1.57B	Tradable Cap1.18B	Total Shares168.65M
T/O13.05M	T/O Rate1.10%	Tradable Shares127.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VIR","market":"US","secType":"STK","nameCN":"Vir Biotechnology, Inc.","latestPrice":9.29,"timestamp":1778529600000,"preClose":9.12,"halted":0,"volume":1392272,"hourTrading":{"tag":"盘后","latestPrice":9.12,"preClose":9.29,"latestTime":"16:26 EDT","volume":12656,"amount":117566.418592,"timestamp":1778531162405,"change":-0.17,"changeRate":-0.018299,"amplitude":0.018299},"delay":0,"changeRate":0.018640350877192978,"floatShares":127000000,"shares":168651974,"eps":-3.140006,"marketStatus":"Post-Mkt","change":0.17,"latestTime":"05-11 17:13:22 EDT","open":9.15,"high":9.645,"low":9.12,"amount":13053715.243755,"amplitude":0.057566,"askPrice":9.9,"askSize":100,"bidPrice":9,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-3.140006,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1778544000000},"marketStatusCode":4,"adr":0,"listingDate":1570766400000,"exchange":"NASDAQ","adjPreClose":9.12,"preHourTrading":{"tag":"盘前","latestPrice":9.14,"preClose":9.12,"latestTime":"09:18 EDT","volume":2061,"amount":18944.108127,"timestamp":1778505499219,"change":0.02,"changeRate":0.002193,"amplitude":0.007675},"postHourTrading":{"tag":"盘后","latestPrice":9.12,"preClose":9.29,"latestTime":"16:26 EDT","volume":12656,"amount":117566.418592,"timestamp":1778531162405,"change":-0.17,"changeRate":-0.018299,"amplitude":0.018299},"volumeRatio":0.821275,"impliedVol":0.3816,"impliedVolPercentile":0.1474},"requestUrl":"/m/hq/s/VIR","defaultTab":"news","newsList":[{"id":"2633486401","title":"Vir Biotechnology (VIR) Gets a Buy from Bank of America Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2633486401","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633486401?lang=en_us&edition=fundamental","pubTime":"2026-05-07 18:37","pubTimestamp":1778150243,"startTime":"0","endTime":"0","summary":"Bank of America Securities analyst Alec Stranahan reiterated a Buy rating on Vir Biotechnology today and set a price target of $16.00. Stranahan co...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/vir-biotechnology-vir-gets-a-buy-from-bank-of-america-securities-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/vir-biotechnology-vir-gets-a-buy-from-bank-of-america-securities-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0256863811.USD","LU0052756011.USD","LU0310800965.SGD","LU2133065610.SGD","LU0868494617.USD","LU1668664300.SGD","LU1791807156.HKD","LU1363072403.SGD","LU0640476718.USD","LU1366192091.USD","LU0203345920.USD","LU1069347547.HKD","LU0070302665.USD","LU0234572021.USD","LU0130102774.USD","LU1894683264.USD","BAC","LU0477156953.USD","BK4535","LU1267930227.SGD","LU1894683348.USD","IE00BZ1G4Q59.USD","BK4139","BK4585","LU2129689514.USD","BK4568","LU0321505439.SGD","LU0306807586.USD","VIR","IE00B19Z3581.USD","LU0149725797.USD","LU1162221912.USD","LU0234570918.USD","LU0306806265.USD","LU0417517546.SGD","PGF","LU0787776722.HKD","BK4207","IE00B7SZLL34.SGD","LU0098860793.USD","LU0130518102.USD","BK4553","BK4504","LU0256863902.USD","LU0130517989.USD","BK4534","LU1880398471.USD","LU0203347892.USD","BK4581","IE00BLSP4452.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633154492","title":"Vir Biotechnology Q1 EPS USD -0.85","url":"https://stock-news.laohu8.com/highlight/detail?id=2633154492","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633154492?lang=en_us&edition=fundamental","pubTime":"2026-05-07 04:19","pubTimestamp":1778098768,"startTime":"0","endTime":"0","summary":"May 06 (Reuters) - Vir Biotechnology Q1 net income USD -125.7 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 06-MAY-202620:05:46.207 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nRSD7zNcnk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4568","BK4585","VIR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633212151","title":"Vir Biotechnology Q1 net loss widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2633212151","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633212151?lang=en_us&edition=fundamental","pubTime":"2026-05-07 04:12","pubTimestamp":1778098371,"startTime":"0","endTime":"0","summary":"Vir Biotechnology Q1 net loss widensOverviewUS biopharma firm's Q1 net loss widened yr/yr as revenue turned negativeCompany ended Q1 with $809.3 mln in cash and investments, excluding Astellas payment","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nL1N41J1CA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4588","VIR","LU0114720955.EUR","LU0109394709.USD","LU0882574055.USD","BK4548","BK4585","BK4139","LU0889565916.HKD","BK4568","LU0320765992.SGD","ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633415904","title":"Vir Biotechnology Q1 2026 GAAP EPS $(0.85) Up From $(0.88) YoY, Sales $(29.000K) Down From $3.032M YoY.","url":"https://stock-news.laohu8.com/highlight/detail?id=2633415904","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633415904?lang=en_us&edition=fundamental","pubTime":"2026-05-07 04:07","pubTimestamp":1778098037,"startTime":"0","endTime":"0","summary":"Vir Biotechnology (NASDAQ:VIR) reported quarterly losses of $(0.85) per share. This is a 3.41 percent increase over losses of $(0.88) per share from the same period last year.  The company reported $(29.000 thousand) in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52342931/vir-biotechnology-q1-2026-gaap-eps-0-85-up-from-0-88-yoy-sales-29-000k-down-from-3-032m-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Vir Biotechnology Q1 2026 GAAP EPS $(0.85) Up From $(0.88) YoY, Sales $(29.000K) Down From $3.032M YoY.","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","VIR","BK4568","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633511131","title":"Vir Biotechnology Inc - Topline Data From Phase 3 Eclipse 1 Trial Expected in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2633511131","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633511131?lang=en_us&edition=fundamental","pubTime":"2026-05-07 04:05","pubTimestamp":1778097901,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nPLX4DDEC7:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4535","VIR","BK4585","BK4139","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633291259","title":"Vir Biotechnology CEO joins Bank of America Securities Healthcare Conference fireside chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2633291259","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633291259?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:17","pubTimestamp":1778012257,"startTime":"0","endTime":"0","summary":"Vir Biotechnology CEO Marianne De Backer will join a fireside chat at Bank of America Securities 2026 Healthcare Conference on May 12 at 4:20 p.m. PT in Las Vegas.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire  on May 05, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nNDL1LwmRg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","VIR","BK4585","BK4139","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633799246","title":"How Insider Sale and VIR-5500 Milestone at Vir Biotechnology (VIR) Have Changed Its Investment Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2633799246","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633799246?lang=en_us&edition=fundamental","pubTime":"2026-05-05 14:19","pubTimestamp":1777961956,"startTime":"0","endTime":"0","summary":"On 1 May 2026, Vir Biotechnology director Vicki L. Sato sold 22,000 shares under a Rule 10b5-1 plan, while the company and Astellas Pharma completed their collaboration agreement and dosed the first patient in a Phase 1 expansion cohort for VIR-5500 in metastatic prostate cancer.\nThis combination of insider selling and tangible progress in Vir’s oncology pipeline highlights the growing importance of VIR-5500 within its broader development portfolio.\nWe’ll now examine how progress on VIR-5500...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vir/vir-biotechnology/news/how-insider-sale-and-vir-5500-milestone-at-vir-biotechnology","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vir/vir-biotechnology/news/how-insider-sale-and-vir-5500-milestone-at-vir-biotechnology","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4535","BK4568","VIR","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633952285","title":"Vir director Vicki L. Sato disposes of 22,000 shares worth $221,025.20","url":"https://stock-news.laohu8.com/highlight/detail?id=2633952285","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633952285?lang=en_us&edition=fundamental","pubTime":"2026-05-05 00:36","pubTimestamp":1777912579,"startTime":"0","endTime":"0","summary":"Vir Biotechnology director Vicki L. Sato sold 22,000 common shares on May 1, 2026.Sale priced at USD 10.05 per share on weighted-average basis.Directly held stake stood at 1,078,391 shares following transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 04, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDLb41hHZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Vir director Vicki L. Sato disposes of 22,000 shares worth $221,025.20","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VIR","BK4568","BK4585","BK4139","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141691535","title":"Earning Preview: Vir Biotechnology, Inc. Q1 revenue is expected to increase by 1,171.96%, and institutional views are bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=1141691535","media":"Earnings Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141691535?lang=en_us&edition=fundamental","pubTime":"2026-04-30 03:47","pubTimestamp":1777492033,"startTime":"0","endTime":"0","summary":"Abstract Vir Biotechnology, Inc. is scheduled to release its quarterly results on May 6, 2026 Post Market; this preview summarizes consensus expectations, last quarter’s performance, the revenue mix...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Earning Preview: Vir Biotechnology, Inc. Q1 revenue is expected to increase by 1,171.96%, and institutional views are bullish","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VIR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630716593","title":"Barclays Remains a Buy on Vir Biotechnology (VIR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2630716593","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630716593?lang=en_us&edition=fundamental","pubTime":"2026-04-28 17:18","pubTimestamp":1777367899,"startTime":"0","endTime":"0","summary":"In a report released today, Etzer Darout from Barclays maintained a Buy rating on Vir Biotechnology, with a price target of $30.00. Darout covers t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-remains-a-buy-on-vir-biotechnology-vir-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-remains-a-buy-on-vir-biotechnology-vir-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4535","VIR","BK4585","BK4139","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629868864","title":"Vir Biotechnology to host conference call on first-quarter results and corporate update","url":"https://stock-news.laohu8.com/highlight/detail?id=2629868864","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629868864?lang=en_us&edition=fundamental","pubTime":"2026-04-24 04:07","pubTimestamp":1776974859,"startTime":"0","endTime":"0","summary":"Vir Biotechnology scheduled conference call for May 6, 2026 at 4:30 p.m. ET to discuss first-quarter 2026 results.Webcast access set via Events & Presentations page on Vir website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire  on April 23, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDL9sMj17:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4535","BK4568","BK4585","VIR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629058630","title":"Vir Biotechnology (VIR) Is Up 19.1% After Astellas Cancer Pact Closes With $315M Inflows","url":"https://stock-news.laohu8.com/highlight/detail?id=2629058630","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629058630?lang=en_us&edition=fundamental","pubTime":"2026-04-21 21:09","pubTimestamp":1776776962,"startTime":"0","endTime":"0","summary":"Vir Biotechnology announced that its global collaboration and licensing agreement with Astellas has closed, bringing in a US$240,000,000 upfront payment, a US$75,000,000 equity investment at US$10.36 per share, and near-term and potential milestone payments tied to the development and commercialization of VIR-5500 for metastatic prostate cancer.\nAt the same time, Vir has begun enrolling an expansion cohort in its Phase 1 trial of VIR-5500 following early safety and anti-tumor signals,...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vir/vir-biotechnology/news/vir-biotechnology-vir-is-up-191-after-astellas-cancer-pact-c","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vir/vir-biotechnology/news/vir-biotechnology-vir-is-up-191-after-astellas-cancer-pact-c","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4568","BK4585","VIR","BK4139","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627215706","title":"Vir Biotechnology closes global collaboration agreement with Astellas Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2627215706","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627215706?lang=en_us&edition=fundamental","pubTime":"2026-04-16 21:17","pubTimestamp":1776345430,"startTime":"0","endTime":"0","summary":"Vir Biotechnology (VIR) announced that its global collaboration and licensing agreement with Astellas (ALPMY) announced on February 23 has closed f...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vir-biotechnology-closes-global-collaboration-agreement-with-astellas-pharma-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vir-biotechnology-closes-global-collaboration-agreement-with-astellas-pharma-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","ALPMY","BK4535","VIR","BK4007","BK4139","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627421369","title":"Vir Biotechnology announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2627421369","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627421369?lang=en_us&edition=fundamental","pubTime":"2026-04-16 20:48","pubTimestamp":1776343695,"startTime":"0","endTime":"0","summary":"Vir Biotechnology scheduled 2026 annual stockholder meeting for May 26, 2026, to be held online.Shareholders will vote on election of three Class I directors: Robert More, Janet Napolitano, Elliott Sigal.Advisory vote set on named executive officer compensation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 16, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nNDL2bMCXn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4568","BK4585","VIR","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627298290","title":"Vir Biotechnology, Astellas form global collaboration on prostate cancer drug VIR-5500","url":"https://stock-news.laohu8.com/highlight/detail?id=2627298290","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627298290?lang=en_us&edition=fundamental","pubTime":"2026-04-16 20:07","pubTimestamp":1776341256,"startTime":"0","endTime":"0","summary":"Vir Biotechnology closed a global collaboration with Astellas to co-develop and co-commercialize prostate cancer therapy candidate VIR-5500.Astellas will make a USD 75 million equity investment at USD 10.36 per share.Deal includes a near-term USD 20 million milestone payment.Vir is eligible for up to USD 1.37 billion in additional milestones, with U.S. profit or loss split 50/50.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nNDL8GcRJw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4535","VIR","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627901632","title":"Vir Biotechnology Announces Closing of Global Strategic Collaboration With Astellas for the Treatment of Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2627901632","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627901632?lang=en_us&edition=fundamental","pubTime":"2026-04-16 20:05","pubTimestamp":1776341100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nTUA6RBD6P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4568","BK4535","VIR","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627290107","title":"Vir Biotechnology Inc - Eligible for $20 Mln Near-Term and up to $1.37 Bln in Additional Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2627290107","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627290107?lang=en_us&edition=fundamental","pubTime":"2026-04-16 20:05","pubTimestamp":1776341100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nTUA6RBD6P:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4139","VIR","BK4568","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627100290","title":"Vir Biotechnology Inc - Receives $240 Mln Upfront and $75 Mln Equity Investment at $10.36 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2627100290","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627100290?lang=en_us&edition=fundamental","pubTime":"2026-04-16 20:05","pubTimestamp":1776341100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nTUA6RBD6P:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","BK4535","BK4585","VIR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627046295","title":"Brii Biosciences files arbitration demand against Vir over elebsiran manufacturing transfer","url":"https://stock-news.laohu8.com/highlight/detail?id=2627046295","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627046295?lang=en_us&edition=fundamental","pubTime":"2026-04-16 17:30","pubTimestamp":1776331822,"startTime":"0","endTime":"0","summary":"Brii Biosciences filed arbitration demand on April 16, 2026 against Vir Biotechnology at US-based JAMS over disputes tied to elebsiran manufacturing transfer.Claims allege Vir breached 2018 collaboration agreement plus December 19, 2024 Sixth Letter Agreement covering transfer of drug product formulation manufacturing responsibility to Brii.Relief sought includes order for specific performance to transfer elebsiran manufacturing to Brii or its contractors.Damages claim seeks recovery for losses to date, including alleged lost profits plus amounts invested in collaboration.Brii said it cannot yet predict outcome or quantify financial impact because proceedings are at an early stage.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brii Bi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nNDL8GJl71:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","VIR","BK1574","02137","BK4535","BK1587","BK4139","BK4585","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627814458","title":"Vir doses first patient in Phase 1 VIR-5500 expansion trial for metastatic prostate cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2627814458","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627814458?lang=en_us&edition=fundamental","pubTime":"2026-04-13 20:08","pubTimestamp":1776082111,"startTime":"0","endTime":"0","summary":"Vir began enrollment in Phase 1 dose-expansion cohorts for VIR-5500, a PSMA-targeted T-cell engager, following dosing of first patient in metastatic prostate cancer study NCT05997615.Phase 1 results were already presented at 2026 ASCO Genitourinary Cancers Symposium, supporting a favorable safety profile and early signs of anti-tumor activity.Expansion cohort will assess whether VIR-5500 can deliver meaningful responses in late-line metastatic castration-resistant prostate cancer.Combination dose escalation with enzalutamide continues, with first patients in combination expansion cohorts expected over coming months.Company plans to move into pivotal Phase 3 trials in 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnolog","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nNDL4GCPLf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4535","VIR","BK4139","BK4568"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vir.bio","stockEarnings":[{"period":"1week","weight":-0.088},{"period":"1month","weight":-0.042},{"period":"3month","weight":0.2684},{"period":"6month","weight":0.7778},{"period":"1year","weight":0.6858},{"period":"ytd","weight":0.5124}],"compareEarnings":[{"period":"1week","weight":0.0235},{"period":"1month","weight":0.0911},{"period":"3month","weight":0.0681},{"period":"6month","weight":0.0993},{"period":"1year","weight":0.3054},{"period":"ytd","weight":0.0817}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. The company was incorporated in 2016 and is headquartered in San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.442895},{"month":2,"riseRate":0.428571,"avgChangeRate":0.063735},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.106207},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.055273},{"month":5,"riseRate":0.571429,"avgChangeRate":0.034408},{"month":6,"riseRate":0.5,"avgChangeRate":0.020036},{"month":7,"riseRate":0.666667,"avgChangeRate":-0.044477},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.0277},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.115495},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.03118},{"month":11,"riseRate":0.857143,"avgChangeRate":0.105555},{"month":12,"riseRate":0.285714,"avgChangeRate":-0.058058}],"exchange":"NASDAQ","name":"Vir Biotechnology, Inc.","nameEN":"Vir Biotechnology, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Vir Biotechnology, Inc.(VIR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Vir Biotechnology, Inc.(VIR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Vir Biotechnology, Inc.,VIR,Vir Biotechnology, Inc.股票,Vir Biotechnology, Inc.股票老虎,Vir Biotechnology, Inc.股票老虎国际,Vir Biotechnology, Inc.行情,Vir Biotechnology, Inc.股票行情,Vir Biotechnology, Inc.股价,Vir Biotechnology, Inc.股市,Vir Biotechnology, Inc.股票价格,Vir Biotechnology, Inc.股票交易,Vir Biotechnology, Inc.股票购买,Vir Biotechnology, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Vir Biotechnology, Inc.(VIR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Vir Biotechnology, Inc.(VIR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction